Biodeal Pharmaceuticals Exits Piramal Alternatives Partnership, Delivering 20%+ IRR

Piramal Alternatives concludes its ₹110 crore investment in Biodeal Pharmaceuticals with over 20% IRR.

Raccontata dahindustantimes.com